Non-Hodgkin's lymphoma

Depends on whether NHL is aggressive or indolent, and on histology, staging, and responsiveness.

In general, patients should be examined and monitored prior to each cycle of chemotherapy, with full blood count (FBC), basic metabolic profile, liver function tests, and lactate dehydrogenase (LDH).

Laboratory parameters including FBC with differential are routinely monitored for severe neutropenia (absolute neutrophil count <500 cells/microlitre [<0.5 × 10⁹/L]).

Restaging with positron emission tomography/computed tomography (PET/CT) during therapy or after therapy completion may help guide subsequent treatment or repeat biopsy for certain lymphomas (e.g., diffuse large B-cell lymphoma).

Patients should be followed up once every 3 months for the first year after treatment, then every 3-6 months for the next 2 years, and 6-12 months thereafter.[174]Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v91-102. https://www.annalsofoncology.org/article/S0923-7534(19)31640-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/27377716?tool=bestpractice.com

Tumour lysis syndrome laboratory tests (LDH, chemistry, uric acid, creatinine, potassium, calcium, and phosphorus) should be monitored, especially for Burkitt's lymphoma.